Caristo Diagnostics
Caristo Diagnostics

Caristo Diagnostics

Revealing hidden heart risk before it's too late

Coronary artery disease is the leading cause of death globally, accounting for 1 in 4 deaths. It’s a major health and economic challenge resulting in $18bn of annual costs in the US alone. Inflammation in the coronary arteries is a major cause – but it’s invisible to standard tests.

Caristo Diagnostics has an AI-powered imaging solution that detects this hidden early pathology on routine CT scans. By spotting early signs of coronary inflammation, its technology enables earlier and better diagnosis, more personalised treatment, and improved outcomes for the world’s leading cause of death.

Sector
HealthTech
Stage
  • Series B+
OSE Manager Limited, a wholly owned subsidiary of Oxford Science Enterprises plc, is authorised and regulated by the Financial Conduct Authority.